Back to Research

Organization profile

EraCal Therapeutics

EraCal Therapeutics is a Swiss biotech spin-off from the University of Zurich and Harvard that develops novel, oral-active anti-obesity drugs. The company utilizes a unique zebrafish phenotypic screening platform to identify first-in-class appetite suppressants with superior potency and safety profiles compared to current standard-of-care.

Basel, SwitzerlandFounded 2018

Overview

1. Executive Summary (Confidence: High)

EraCal Therapeutics AG, incorporated in 2018, is a high-trajectory biotech firm disrupting the metabolic disease landscape. The firm’s "Front-Running Program," Era-379, was outlicensed to Novo Nordisk in January 2024 for €235 million plus royalties, a deal that cements EraCal’s status as a leader in "next-generation anti-obesity pharmacotherapy". EraCal’s competitive edge is its peer-reviewed zebrafish drug discovery platform, which enables high-throughput, whole-organism phenotypic screening of human-relevant molecules. Beyond its pharma partnership with Novo Nordisk, the company is also collaborating with Nestlé Health Science to develop novel nutraceuticals, positioning itself as a "multi-vertical" innovator in metabolic health.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.